# A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Source: https://onco.cc/trials/nct07103668/  
OnCo record `nct07103668` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of CAR T cells in gastric & gastro-oesophageal junction cancer, run by Suzhou Immunofoco Biotechnology Co., Ltd, now recruiting.

## Summary

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients is a phase 3 interventional study registered as NCT07103668 by Suzhou Immunofoco Biotechnology Co., Ltd, with 150 participants planned, started 2025-08-06 and due to reach its primary completion in 2027-05-31. Interventions recorded: CAR T cells and Control.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07103668
- Phase: 3
- Setting: An Open-label, Randomized, Comparative Phase III Study Including Patients With CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer.
- Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07103668: https://clinicaltrials.gov/study/NCT07103668

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)

---
JSON: https://onco.cc/api/v1/entities/nct07103668.json